➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,526,764

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,526,764
Title:Combination of an insulin and a GLP-1-agonist
Abstract: The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
Inventor(s): Werner; Ulrich (Frankfurt am Main, DE), Rotthauser; Barbel (Frankfurt am Main, DE)
Application Number:13/123,835
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,526,764

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,526,764

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2008 051 834Oct 17, 2008
Germany10 2008 053 048Oct 24, 2008
Germany10 2009 038 210Aug 20, 2009
PCT Information
PCT FiledOctober 09, 2009PCT Application Number:PCT/EP2009/063195
PCT Publication Date:April 22, 2010PCT Publication Number: WO2010/043566

International Family Members for US Patent 9,526,764

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 073872   Start Trial
Australia 2009305472   Start Trial
Brazil 122013025625   Start Trial
Brazil PI0920881   Start Trial
Canada 2740685   Start Trial
Canada 3016451   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.